Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy

Abstract

PurposeTo determine the efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% preserved with polyquaternium-1 in patients with insufficient response to bimatoprost 0.03%/timolol 0.5% preserved with benzalkonium chloride.Patients and methodsIn this open-label nonrandomized study conducted at 13 European sites, patients with primary open-angle glaucoma or ocular hypertension with insufficient intraocular pressure (IOP) reduction during bimatoprost/timolol therapy were transitioned to travoprost/timolol (DuoTrav®) administered every evening for 12 weeks. Change in IOP from baseline to week 12 was assessed in patients who transitioned from fixed-combination bimatoprost/timolol (n=57, primary endpoint). Secondary assessments included change in IOP at week 4, percentage of patients with IOP ≤18 mmHg at weeks 4 and 12, change in Ocular Surface Disease Index and ocular hyperemia scores at week 12, and patient preference. Adverse events were also reported.ResultsIOP change (mean ± SD) from baseline to week 12 was –3.8±1.9 mmHg (P<0.001); results were similar at week 4. Most patients had IOP ≤18 mmHg at weeks 4 and 12 (78.6% and 85.5%, respectively). Mean Ocular Surface Disease Index score was significantly reduced (P<0.001); no significant change in ocular hyperemia score was observed (P=0.197). Treatment-related adverse events included dysgeusia, nausea, paresthesia, myalgia, headache, and eye irritation (n=1 each). Most patients (74.5%) preferred travoprost/timolol over bimatoprost/timolol.ConclusionTransition to travoprost/timolol significantly reduced IOP and was well tolerated in patients who had elevated IOP despite bimatoprost/timolol therapy. Polyquaternium-1–preserved travoprost/timolol was preferred over prior treatment with benzalkonium chloride–preserved bimatoprost/timolol.

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study

“…Moreover, in this study, also no washout period was established between run-in period and final visit. 27 This IOP reduction is comparable to our results, even when considering the approximately 1 mmHg higher baseline IOP level.…”

“…In a study evaluating the effects of a change of medication from a fixed combination of bimatoprost and timolol to a fixed combination of travoprost and timolol, mean IOP was reduced from 20.0 to 16.8 mmHg (−18.5%) after 12 weeks. Moreover, in this study, also no washout period was established between run-in period and final visit 27. This IOP reduction is comparable to our results, even when considering the approximately 1 mmHg higher baseline IOP level.…”

Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study

“…Many factors contribute to the development of glaucoma; however, intraocular pressure (IOP) is the most important factor. The control of IOP is currently the only management option for glaucoma [ 1 – 3 ].…”

“…Many anti-glaucoma drugs are delivered via eyedrops, but the effects of lowering IOP vary from 10 to 30% [ 1 – 3 ]. Glaucoma patients typically use anti-glaucoma eyedrops for a long time.…”

Efficacy of Bimatoprost Plus Timolol Fixed Combination in Open Angle Glaucoma Patients Previously Treated with Dorzolamide Plus Timolol Fixed Combination

“…and co-authors showed an additional IOP lowering effect when patients previously treated with BTFC were changed to travoprost plus timolol FC. 22 Aptel and co-workers performed a meta-analysis of clinical trials comparing the different prostaglandin plus timolol FCs and they concluded that a greater IOP lowering efficacy was achieved with BTFC compared with either travoprost or latanoprost plus timolol FC. 23 Few studies have compared prostaglandin plus timolol FC with carbonic anhydrase inhibitor plus timolol FC.…”